ACADIA Pharmaceuticals Inc.
ACAD · NASDAQ
Earnings history and estimates
Reported and estimated revenue, EPS and post-earnings movement.
| Period | Date | Revenue actual | Revenue estimate | EPS actual | EPS estimate | 1D move |
|---|---|---|---|---|---|---|
| 2026 Q2 | August 4, 2026 | — | 295.83M | — | 0.05 | — |
| 2026 Q1 | May 6, 2026 | 268.06M | 280.25M | 0.02 | 0.04 | +5.03% |
| 2025 Q4 | February 25, 2026 | 283.99M | 292.79M | 1.60 | 0.12 | -1.32% |
| 2025 Q3 | November 5, 2025 | 278.63M | 292.59M | 0.26 | 0.14 | -3.05% |
| 2025 Q2 | August 6, 2025 | 264.57M | 262.00M | 0.16 | 0.14 | +2.52% |
| 2025 Q1 | May 7, 2025 | 244.32M | 238.97M | 0.11 | 0.10 | +14.31% |
| 2024 Q4 | February 26, 2025 | 259.60M | 273.04M | 0.17 | 0.19 | +1.79% |
| 2024 Q3 | November 6, 2024 | 250.40M | 282.92M | 0.20 | 0.13 | +8.93% |
| 2024 Q2 | August 6, 2024 | 241.96M | 235.42M | 0.20 | 0.16 | -19.52% |
| 2024 Q1 | May 8, 2024 | 205.83M | 208.29M | 0.10 | 0.04 | -11.21% |
| 2023 Q4 | February 27, 2024 | 231.04M | 223.78M | 0.28 | 0.32 | -9.92% |
| 2023 Q3 | November 2, 2023 | 211.70M | 224.38M | -0.40 | -0.43 | +4.70% |
| 2023 Q2 | August 2, 2023 | 165.24M | 157.85M | 0.01 | -0.12 | -6.85% |
| 2023 Q1 | May 8, 2023 | 118.46M | 120.08M | -0.27 | -0.21 | -0.56% |
| 2022 Q4 | February 27, 2023 | 136.49M | 134.23M | -0.26 | -0.25 | +6.65% |
| 2022 Q3 | November 2, 2022 | 130.71M | 138.76M | -0.17 | -0.18 | -6.97% |